Amarin Plans Additional Miraxion Phase III Trial To Support Huntington’s NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amarin's beleaguered neuroprotective agent Miraxion (ethyl eicosapentaenoate) gained new life Nov. 15 when FDA said an additional Phase III trial might help its case for approval as a Huntington's disease therapy, the firm announced Nov. 19
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.